| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pulmonary Disease, Chronic Obstructive | 41 | 2021 | 3832 | 4.38 | Why? |
| Muscarinic Antagonists | 16 | 2019 | 176 | 4.21 | Why? |
| Bronchodilator Agents | 24 | 2019 | 444 | 3.56 | Why? |
| Asthma | 27 | 2020 | 4383 | 3.35 | Why? |
| Adrenergic beta-2 Receptor Agonists | 12 | 2019 | 142 | 3.18 | Why? |
| Allergens | 9 | 2019 | 728 | 2.98 | Why? |
| Anti-Asthmatic Agents | 8 | 2019 | 427 | 2.50 | Why? |
| Tiotropium Bromide | 6 | 2018 | 46 | 2.44 | Why? |
| Glycopyrrolate | 3 | 2018 | 51 | 2.04 | Why? |
| Prostate-Specific Antigen | 3 | 2017 | 213 | 1.85 | Why? |
| Indans | 2 | 2018 | 54 | 1.40 | Why? |
| Idiopathic Pulmonary Fibrosis | 6 | 2019 | 595 | 1.34 | Why? |
| Quinolones | 2 | 2018 | 167 | 1.26 | Why? |
| Adrenal Cortex Hormones | 15 | 2020 | 6537 | 1.20 | Why? |
| Administration, Inhalation | 15 | 2020 | 1647 | 1.19 | Why? |
| Bronchi | 8 | 2018 | 1048 | 1.19 | Why? |
| Hypersensitivity | 4 | 2019 | 1137 | 1.10 | Why? |
| Dogs | 7 | 2019 | 2529 | 1.00 | Why? |
| Desensitization, Immunologic | 2 | 2018 | 574 | 0.94 | Why? |
| Lipocalins | 2 | 2018 | 19 | 0.94 | Why? |
| Nasal Provocation Tests | 1 | 2019 | 12 | 0.82 | Why? |
| Rhinitis, Allergic, Seasonal | 1 | 2021 | 121 | 0.82 | Why? |
| Dander | 1 | 2019 | 1 | 0.81 | Why? |
| Animal Fur | 1 | 2018 | 11 | 0.78 | Why? |
| Asthma, Occupational | 1 | 2018 | 6 | 0.78 | Why? |
| Anaphylaxis | 3 | 2018 | 940 | 0.77 | Why? |
| Albumins | 2 | 2018 | 324 | 0.76 | Why? |
| Bronchial Hyperreactivity | 1 | 2018 | 38 | 0.74 | Why? |
| Beclomethasone | 1 | 2018 | 32 | 0.71 | Why? |
| Rhinitis, Allergic, Perennial | 1 | 2017 | 36 | 0.71 | Why? |
| Formoterol Fumarate | 1 | 2018 | 61 | 0.70 | Why? |
| Loratadine | 1 | 2017 | 18 | 0.69 | Why? |
| Animals, Laboratory | 1 | 2017 | 40 | 0.67 | Why? |
| Pets | 2 | 2018 | 314 | 0.66 | Why? |
| Aminopyridines | 1 | 2017 | 121 | 0.65 | Why? |
| Nebulizers and Vaporizers | 2 | 2020 | 497 | 0.65 | Why? |
| Histamine H1 Antagonists | 1 | 2017 | 79 | 0.64 | Why? |
| Sublingual Immunotherapy | 1 | 2017 | 88 | 0.64 | Why? |
| Oxytocin | 1 | 2017 | 76 | 0.63 | Why? |
| Pharmacogenetics | 1 | 2018 | 222 | 0.63 | Why? |
| Diagnostic Self Evaluation | 1 | 2020 | 394 | 0.61 | Why? |
| Pathology, Molecular | 1 | 2019 | 343 | 0.61 | Why? |
| Pregnenediones | 1 | 2017 | 182 | 0.60 | Why? |
| Macrophages, Alveolar | 1 | 2019 | 668 | 0.59 | Why? |
| Hypersensitivity, Immediate | 1 | 2017 | 134 | 0.58 | Why? |
| Hair | 1 | 2017 | 175 | 0.57 | Why? |
| Benzamides | 1 | 2017 | 421 | 0.57 | Why? |
| Dermatitis, Allergic Contact | 1 | 2017 | 185 | 0.55 | Why? |
| Disease Progression | 7 | 2020 | 13580 | 0.52 | Why? |
| Glucocorticoids | 3 | 2018 | 4431 | 0.51 | Why? |
| Horse Diseases | 3 | 2018 | 101 | 0.48 | Why? |
| Bronchoscopy | 1 | 2020 | 991 | 0.47 | Why? |
| Acetylcysteine | 4 | 2018 | 255 | 0.46 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.46 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2020 | 2309 | 0.46 | Why? |
| Semen | 1 | 2017 | 550 | 0.46 | Why? |
| Food Hypersensitivity | 1 | 2017 | 397 | 0.45 | Why? |
| Chemokines | 1 | 2018 | 1095 | 0.45 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.44 | Why? |
| Bias | 1 | 2017 | 1109 | 0.44 | Why? |
| Medication Adherence | 2 | 2019 | 1270 | 0.44 | Why? |
| Dyspnea | 4 | 2021 | 3847 | 0.43 | Why? |
| Expectorants | 4 | 2019 | 95 | 0.43 | Why? |
| Forced Expiratory Volume | 6 | 2019 | 632 | 0.43 | Why? |
| Pulmonary Fibrosis | 1 | 2020 | 1068 | 0.42 | Why? |
| Immunoglobulin E | 3 | 2019 | 557 | 0.42 | Why? |
| Drug Therapy, Combination | 10 | 2019 | 7268 | 0.42 | Why? |
| Sulfhydryl Compounds | 2 | 2021 | 104 | 0.39 | Why? |
| Exercise Tolerance | 4 | 2018 | 634 | 0.39 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.38 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.38 | Why? |
| Perception | 1 | 2020 | 2827 | 0.37 | Why? |
| Scopolamine Derivatives | 2 | 2018 | 10 | 0.37 | Why? |
| Lung | 9 | 2020 | 31049 | 0.36 | Why? |
| Network Meta-Analysis | 4 | 2018 | 426 | 0.36 | Why? |
| Cholinergic Agents | 2 | 2018 | 26 | 0.36 | Why? |
| Humans | 100 | 2021 | 930598 | 0.36 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.35 | Why? |
| Adrenergic beta-Agonists | 2 | 2018 | 93 | 0.35 | Why? |
| Delayed-Action Preparations | 3 | 2018 | 291 | 0.35 | Why? |
| Cholinergic Antagonists | 2 | 2018 | 56 | 0.35 | Why? |
| Benzoxazines | 2 | 2018 | 103 | 0.34 | Why? |
| Drug Combinations | 6 | 2018 | 3852 | 0.33 | Why? |
| Drug Delivery Systems | 1 | 2017 | 1365 | 0.33 | Why? |
| Animals | 25 | 2019 | 78931 | 0.32 | Why? |
| Respiratory Function Tests | 3 | 2018 | 1755 | 0.32 | Why? |
| Chronic Disease | 3 | 2020 | 5139 | 0.32 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.28 | Why? |
| Reactive Oxygen Species | 3 | 2021 | 1136 | 0.28 | Why? |
| Thioglycolates | 3 | 2019 | 12 | 0.28 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2019 | 10649 | 0.27 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2018 | 9335 | 0.27 | Why? |
| Quality of Life | 6 | 2018 | 9820 | 0.26 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.26 | Why? |
| Thiophenes | 3 | 2019 | 78 | 0.26 | Why? |
| Disease Management | 3 | 2017 | 6841 | 0.25 | Why? |
| General Practice | 1 | 2011 | 718 | 0.24 | Why? |
| Drug Prescriptions | 1 | 2011 | 1062 | 0.24 | Why? |
| Neurokinin A | 2 | 2018 | 7 | 0.24 | Why? |
| Cross Reactions | 3 | 2018 | 4374 | 0.24 | Why? |
| Cardiovascular Diseases | 5 | 2021 | 11497 | 0.23 | Why? |
| Cats | 2 | 2019 | 1890 | 0.23 | Why? |
| Eosinophils | 5 | 2019 | 848 | 0.22 | Why? |
| Occupational Diseases | 1 | 2017 | 2787 | 0.22 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.22 | Why? |
| Oxidative Stress | 4 | 2021 | 2050 | 0.22 | Why? |
| Anti-Inflammatory Agents | 4 | 2019 | 6153 | 0.22 | Why? |
| Interleukin-5 | 2 | 2018 | 138 | 0.22 | Why? |
| Organ Culture Techniques | 2 | 2018 | 119 | 0.22 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.22 | Why? |
| Drug Synergism | 3 | 2018 | 833 | 0.21 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.21 | Why? |
| Phosphodiesterase 4 Inhibitors | 2 | 2019 | 112 | 0.20 | Why? |
| Receptors, Transferrin | 1 | 2019 | 72 | 0.20 | Why? |
| Treatment Outcome | 15 | 2020 | 51732 | 0.20 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2018 | 6166 | 0.20 | Why? |
| Pyrimidinones | 1 | 2019 | 76 | 0.20 | Why? |
| Animal Technicians | 1 | 2018 | 11 | 0.20 | Why? |
| Isoquinolines | 1 | 2019 | 69 | 0.19 | Why? |
| Horses | 5 | 2018 | 474 | 0.19 | Why? |
| Lung Diseases, Fungal | 1 | 2020 | 167 | 0.19 | Why? |
| Histone Deacetylase 2 | 1 | 2018 | 12 | 0.19 | Why? |
| Bronchitis, Chronic | 1 | 2017 | 15 | 0.18 | Why? |
| Theophylline | 1 | 2018 | 39 | 0.18 | Why? |
| Mevalonic Acid | 1 | 2018 | 24 | 0.18 | Why? |
| Practice Patterns, Physicians' | 3 | 2017 | 4927 | 0.18 | Why? |
| Veterinarians | 1 | 2018 | 49 | 0.18 | Why? |
| Afferent Pathways | 1 | 2017 | 7 | 0.18 | Why? |
| Benzyl Alcohols | 1 | 2017 | 22 | 0.18 | Why? |
| Chlorobenzenes | 1 | 2017 | 35 | 0.18 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.18 | Why? |
| Latex | 1 | 2017 | 9 | 0.18 | Why? |
| Intradermal Tests | 1 | 2017 | 15 | 0.17 | Why? |
| Quinuclidines | 1 | 2017 | 22 | 0.17 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 1454 | 0.17 | Why? |
| Lung Volume Measurements | 1 | 2017 | 115 | 0.17 | Why? |
| Administration, Sublingual | 1 | 2017 | 41 | 0.17 | Why? |
| Basigin | 1 | 2020 | 276 | 0.17 | Why? |
| Male | 30 | 2021 | 367725 | 0.17 | Why? |
| Classification | 1 | 2017 | 55 | 0.17 | Why? |
| Self Report | 2 | 2021 | 3802 | 0.17 | Why? |
| Precision Medicine | 2 | 2017 | 1477 | 0.17 | Why? |
| Dry Powder Inhalers | 1 | 2017 | 36 | 0.17 | Why? |
| Albuterol | 1 | 2017 | 105 | 0.17 | Why? |
| Pneumonia, Pneumococcal | 1 | 2020 | 251 | 0.17 | Why? |
| Microarray Analysis | 1 | 2018 | 262 | 0.16 | Why? |
| Respiratory Physiological Phenomena | 1 | 2018 | 157 | 0.16 | Why? |
| Respiratory Hypersensitivity | 1 | 2018 | 103 | 0.16 | Why? |
| Comparative Effectiveness Research | 1 | 2017 | 178 | 0.16 | Why? |
| Omalizumab | 1 | 2019 | 158 | 0.16 | Why? |
| Vasopressins | 1 | 2017 | 70 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Haplotypes | 1 | 2020 | 853 | 0.16 | Why? |
| Mental Disorders | 1 | 2020 | 6742 | 0.16 | Why? |
| Metered Dose Inhalers | 1 | 2017 | 46 | 0.16 | Why? |
| Blood Gas Analysis | 1 | 2020 | 893 | 0.16 | Why? |
| Tablets | 1 | 2017 | 219 | 0.16 | Why? |
| Lipopolysaccharides | 2 | 2018 | 848 | 0.16 | Why? |
| Dose-Response Relationship, Drug | 4 | 2018 | 3776 | 0.16 | Why? |
| Female | 29 | 2021 | 380317 | 0.16 | Why? |
| Molecular Mimicry | 1 | 2017 | 190 | 0.15 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.15 | Why? |
| Eosinophilia | 1 | 2019 | 292 | 0.15 | Why? |
| Pneumonia, Bacterial | 2 | 2020 | 843 | 0.15 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.15 | Why? |
| Protective Agents | 1 | 2018 | 250 | 0.15 | Why? |
| Decision Trees | 1 | 2017 | 441 | 0.14 | Why? |
| Cellular Senescence | 1 | 2018 | 326 | 0.14 | Why? |
| Fungi | 1 | 2018 | 471 | 0.14 | Why? |
| Dysgeusia | 1 | 2020 | 524 | 0.14 | Why? |
| Anxiety Disorders | 2 | 2018 | 2290 | 0.14 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.14 | Why? |
| Dyslipidemias | 1 | 2021 | 791 | 0.14 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.14 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.14 | Why? |
| HLA Antigens | 1 | 2020 | 830 | 0.14 | Why? |
| Antioxidants | 3 | 2019 | 1593 | 0.13 | Why? |
| Anti-Bacterial Agents | 5 | 2019 | 10083 | 0.13 | Why? |
| Respiratory Tract Infections | 4 | 2018 | 6817 | 0.13 | Why? |
| Herpesvirus 1, Human | 1 | 2017 | 286 | 0.13 | Why? |
| Awareness | 1 | 2018 | 529 | 0.13 | Why? |
| Mediastinal Emphysema | 1 | 2021 | 519 | 0.13 | Why? |
| Spirometry | 1 | 2017 | 524 | 0.13 | Why? |
| Infliximab | 1 | 2018 | 502 | 0.13 | Why? |
| Aged | 19 | 2021 | 215776 | 0.13 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.13 | Why? |
| Specialization | 1 | 2017 | 432 | 0.12 | Why? |
| Furin | 1 | 2020 | 1054 | 0.12 | Why? |
| Pneumonia, Viral | 9 | 2021 | 243684 | 0.12 | Why? |
| Species Specificity | 1 | 2017 | 1356 | 0.12 | Why? |
| Italy | 9 | 2021 | 38444 | 0.12 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.12 | Why? |
| Pulmonary Medicine | 1 | 2019 | 706 | 0.12 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.11 | Why? |
| Withholding Treatment | 1 | 2017 | 798 | 0.11 | Why? |
| Staphylococcal Infections | 1 | 2020 | 1099 | 0.11 | Why? |
| Rats | 1 | 2018 | 2764 | 0.11 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.11 | Why? |
| Urticaria | 1 | 2017 | 472 | 0.11 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.10 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.10 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.10 | Why? |
| Headache | 1 | 2020 | 2257 | 0.10 | Why? |
| Severity of Illness Index | 9 | 2019 | 48226 | 0.09 | Why? |
| Hypertension, Pulmonary | 1 | 2018 | 970 | 0.09 | Why? |
| Biomarkers | 5 | 2021 | 23361 | 0.09 | Why? |
| Cardiovascular System | 1 | 2017 | 750 | 0.09 | Why? |
| Genetic Predisposition to Disease | 2 | 2020 | 4027 | 0.09 | Why? |
| Adolescent | 8 | 2020 | 86841 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.09 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.09 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.09 | Why? |
| Aged, 80 and over | 8 | 2020 | 88759 | 0.08 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.08 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.08 | Why? |
| Thorax | 1 | 2017 | 1873 | 0.08 | Why? |
| Lung Diseases, Interstitial | 1 | 2018 | 1476 | 0.08 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.08 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.08 | Why? |
| Electrocardiography | 1 | 2021 | 3957 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Pharmacists | 1 | 2017 | 1246 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Risk | 1 | 2018 | 5288 | 0.08 | Why? |
| Vital Capacity | 2 | 2018 | 399 | 0.08 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.08 | Why? |
| Equipment Design | 1 | 2017 | 3095 | 0.08 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.07 | Why? |
| Anxiety | 4 | 2020 | 17311 | 0.07 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.07 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.07 | Why? |
| Nanoparticles | 1 | 2017 | 2040 | 0.07 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.07 | Why? |
| Prognosis | 5 | 2019 | 32490 | 0.07 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.07 | Why? |
| Pneumonia | 3 | 2018 | 5652 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.06 | Why? |
| Communication | 2 | 2021 | 5206 | 0.06 | Why? |
| Cough | 1 | 2017 | 4891 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| African Americans | 1 | 2018 | 3363 | 0.06 | Why? |
| Social Support | 1 | 2017 | 3183 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.06 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2019 | 3228 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Diabetes Mellitus | 2 | 2021 | 8207 | 0.06 | Why? |
| Child | 6 | 2020 | 70012 | 0.06 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.06 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Percutaneous Coronary Intervention | 1 | 2018 | 3646 | 0.05 | Why? |
| Hypesthesia | 1 | 2020 | 60 | 0.05 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Mutation | 1 | 2020 | 12376 | 0.05 | Why? |
| Paresthesia | 1 | 2020 | 134 | 0.05 | Why? |
| Phosphodiesterase 3 Inhibitors | 1 | 2019 | 25 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Occupational Exposure | 1 | 2018 | 4742 | 0.05 | Why? |
| Adult | 12 | 2021 | 244371 | 0.05 | Why? |
| Leukocyte Count | 2 | 2020 | 3178 | 0.05 | Why? |
| Parietaria | 1 | 2018 | 2 | 0.05 | Why? |
| Dissent and Disputes | 1 | 2021 | 117 | 0.05 | Why? |
| Dermatophagoides pteronyssinus | 1 | 2018 | 3 | 0.05 | Why? |
| Microdialysis | 1 | 2018 | 22 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Exome | 1 | 2020 | 207 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Cystic Fibrosis | 2 | 2019 | 1104 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Bronchoconstriction | 1 | 2018 | 16 | 0.05 | Why? |
| Illness Behavior | 1 | 2018 | 76 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.05 | Why? |
| rho-Associated Kinases | 1 | 2018 | 32 | 0.05 | Why? |
| Interleukin-5 Receptor alpha Subunit | 1 | 2017 | 6 | 0.05 | Why? |
| Mice | 1 | 2018 | 21357 | 0.05 | Why? |
| Capsaicin | 1 | 2018 | 19 | 0.05 | Why? |
| Depression | 2 | 2020 | 14116 | 0.05 | Why? |
| Acetylation | 1 | 2018 | 124 | 0.05 | Why? |
| Carbocysteine | 1 | 2017 | 4 | 0.05 | Why? |
| Simvastatin | 1 | 2018 | 63 | 0.05 | Why? |
| Electric Stimulation | 1 | 2018 | 84 | 0.04 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.04 | Why? |
| Surveys and Questionnaires | 4 | 2018 | 43792 | 0.04 | Why? |
| Whole Exome Sequencing | 1 | 2020 | 437 | 0.04 | Why? |
| Drug Administration Routes | 1 | 2018 | 106 | 0.04 | Why? |
| Pulmonary Diffusing Capacity | 1 | 2018 | 191 | 0.04 | Why? |
| Inspiratory Capacity | 1 | 2017 | 47 | 0.04 | Why? |
| Cinnamates | 1 | 2018 | 50 | 0.04 | Why? |
| Ambroxol | 1 | 2017 | 45 | 0.04 | Why? |
| Dizziness | 1 | 2020 | 275 | 0.04 | Why? |
| Pollen | 1 | 2018 | 137 | 0.04 | Why? |
| Gastroesophageal Reflux | 1 | 2019 | 124 | 0.04 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.04 | Why? |
| Muscle, Smooth | 1 | 2017 | 67 | 0.04 | Why? |
| Muscle Contraction | 1 | 2017 | 60 | 0.04 | Why? |
| Anilides | 1 | 2018 | 105 | 0.04 | Why? |
| Bronchitis | 1 | 2018 | 146 | 0.04 | Why? |
| Death, Sudden | 1 | 2019 | 160 | 0.04 | Why? |
| Lung Transplantation | 2 | 2019 | 1554 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Tissue Distribution | 1 | 2018 | 483 | 0.04 | Why? |
| Airway Resistance | 1 | 2017 | 83 | 0.04 | Why? |
| Biological Availability | 1 | 2018 | 388 | 0.04 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.04 | Why? |
| Respiratory Insufficiency | 1 | 2018 | 7301 | 0.04 | Why? |
| Airway Remodeling | 1 | 2017 | 111 | 0.04 | Why? |
| Glutathione | 1 | 2018 | 280 | 0.04 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| Drug Design | 2 | 2018 | 2627 | 0.04 | Why? |
| Walk Test | 1 | 2018 | 461 | 0.04 | Why? |
| Airway Obstruction | 1 | 2018 | 182 | 0.04 | Why? |
| Gene Frequency | 1 | 2020 | 1210 | 0.04 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.04 | Why? |
| Respiration | 1 | 2021 | 729 | 0.04 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 449 | 0.04 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 436 | 0.03 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.03 | Why? |
| Alleles | 1 | 2020 | 1557 | 0.03 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Dipeptidyl Peptidase 4 | 1 | 2020 | 1061 | 0.03 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.03 | Why? |
| Sex Distribution | 1 | 2020 | 2083 | 0.03 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.03 | Why? |
| Patients | 1 | 2020 | 1167 | 0.03 | Why? |
| Cell Survival | 1 | 2018 | 1581 | 0.03 | Why? |
| Pneumothorax | 1 | 2021 | 758 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.03 | Why? |
| Exercise Test | 1 | 2018 | 911 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
| Rhinitis, Allergic | 1 | 2019 | 704 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Inflammation | 3 | 2018 | 13255 | 0.03 | Why? |
| Stroke Volume | 1 | 2021 | 2153 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.03 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.03 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2020 | 1463 | 0.02 | Why? |
| Smoking Cessation | 1 | 2017 | 826 | 0.02 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| Sleep | 1 | 2020 | 2695 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Dexamethasone | 1 | 2018 | 2055 | 0.02 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.02 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.02 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.01 | Why? |
| Aging | 1 | 2018 | 3581 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Obesity | 1 | 2019 | 7388 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.01 | Why? |